GET DAILY SIGNALSNextPlat (NXPL) Slides -29% Over 30 Days: Earnings and Dilution Factors at Play
Key Takeaways
- NextPlat shares have dropped roughly 29% over the past 30 days, falling from about $9.01 on October 13 to near $6.38.
- The bulk of the decline came in a sharp single-session selloff of about 21% after third-quarter results were released.
- Third-quarter 2026 revenue declined year over year to approximately $10.5 million, even as gross margin held near 35% and the net loss narrowed by about 66%.
- The stock had rallied strongly earlier in the quarter, climbing from roughly $6 in early August to above $9 by mid-October, before reversing course.
- Key factors to monitor include potential share dilution from an at-the-market equity program, a recent reverse stock split, and execution on the healthcare growth strategy.
- NextPlat operates two segments: satellite-connectivity e-commerce and U.S. pharmacy and healthcare services through its Progressive Care subsidiary.
- For additional context, explore NXPL price targets, earnings, and forecast pages.
- Discover how AI-powered strategies are tracking this and other tickers by visiting the Trending AI Robots page.
Company Snapshot: NextPlat’s Dual Focus on Healthcare and Connectivity
NextPlat Corp operates as a global provider of consumer products and services, delivering healthcare and technology solutions through e-commerce and retail channels. Based in Coconut Grove, Florida, the company runs two primary segments. Its e-commerce communications division supplies voice, data, tracking, and IoT products, including satellite-connectivity devices from manufacturers such as GSAT and IRDM. The U.S. healthcare segment, managed through the wholly owned Progressive Care subsidiary, offers pharmacy and healthcare data-management services.
The PharmcoRx platform serves retail, 340B, long-term care, government, and specialty pharmacy clients, backed by the proprietary ClearMetrX data-analytics software. NextPlat has also developed an e-commerce channel for OPK-branded products in Asia. I think investors track NXPL for its progress toward profitability, margin expansion, and growth in contracted healthcare services. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance: 30-Day Drop Versus the Broader Quarter
Over the last 30 days, NXPL has declined approximately 29%, moving from a closing price near $9.01 on October 13 to roughly $6.38. The decline was sharp rather than gradual. The stock held in the $8.00 to $9.00 range for much of the period before a single-session drop of about 21% following the third-quarter results.
The quarter-to-date view shows more movement. NextPlat started the period in early August near $6.00, climbed through late summer, and reached a local peak of about $9.68 in mid-October. That rally gave way to a reversal, leaving the stock roughly 5% lower over the trailing three months despite the earlier gains. From what I see, the pattern highlights both the volatility and the sensitivity to quarterly updates.
Drivers Behind the Recent 30-Day Decline
The main catalyst was the third-quarter 2026 earnings release in mid-November, which prompted the sharp single-day selloff. NextPlat reported consolidated gross margins of approximately 35% and a roughly 66% reduction in net loss, yet revenue fell year over year to about $10.5 million from $13.8 million. Investor attention also turned to share-count dynamics after a 2026 reverse stock split to meet Nasdaq requirements and the launch of an at-the-market equity program with H.C. Wainwright. In my view, the revenue comparison, ongoing losses, and potential dilution outweighed the margin and cost-control improvements during that window.
Broader Quarter: Turnaround Momentum and Subsequent Reversal
Over the full quarter, NextPlat’s stock reflected an improving operational story that later encountered profit-taking and post-earnings pressure. In late summer, shares advanced on signs of progress, including record 340B contract wins, rollout of the AI-powered ClearMetrX 4.0 platform, and the acquisition of a profitable Florida pharmacy near Pensacola that added roughly $5.6 million in annual revenue. The company also expanded its satellite-connectivity reach through a Decathlon partnership covering 20 countries and noted solid demand for connectivity hardware. That momentum carried the stock to multi-month highs by mid-October before the revenue shortfall and dilution concerns triggered the reversal.
Key Areas to Monitor for NXPL Going Forward
Looking ahead, attention will center on whether NextPlat can restore revenue growth while holding gross margins near 35%. The planned fourth-quarter launch of a nationwide medication-fulfillment website stands out as a near-term catalyst that could extend PharmcoRx beyond Florida. Other items to watch include the ramp of new 340B contracts, demand for satellite-connectivity products, potential additional pharmacy acquisitions in Florida, and the pace of any share issuance under the at-the-market program. Macroeconomic and reimbursement trends in the U.S. pharmacy sector, along with the path to positive operating income, will also influence sentiment. These remain forward-looking considerations rather than forecasts.
Reviewing AI-Driven Signals for Additional Perspective
When analyzing names like NXPL, I sometimes cross-reference automated strategies to gain another angle on market positioning. Tickeron’s Trending AI Robots page highlights a curated selection of top-performing AI-powered trading bots drawn from a wide universe. Only consistently relevant strategies appear, offering a focused view of how automated systems are positioned across various tickers and timeframes. This can provide useful context for volatile micro-caps without replacing fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NXPL's Stochastic Oscillator remains in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NXPL as a result. In 85 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for NXPL turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 52 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NXPL moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NXPL crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NXPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NXPL entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NXPL's RSI Oscillator exited the oversold zone, 28 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +14.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NXPL advanced for three days, in 199 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
NXPL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.364) is normal, around the industry mean (-1.906). P/E Ratio (-2.402) is within average values for comparable stocks, (9.554). Projected Growth (PEG Ratio) (0.180) is also within normal values, averaging (2.824). Dividend Yield (0.000) settles around the average of (0.069) among similar stocks. P/S Ratio (0.494) is also within normal values, averaging (70.383).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NXPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NXPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PackagedSoftware
Advertisement